With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5271-27-2,1-Methyl-3-phenylpiperazine,as a common compound, the synthetic route is as follows.,5271-27-2
1-Methyl-3-phenyl-piperazine (31.7 mg, 0.18 mmol) were weighted into a reaction vial and dissolved in 1 ml THF. 1 ml of a DMF stock solution containing N-methylmorpholine (51 mg, 0.5 mmol), 6-(4-Hydroxy-phenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid (48 mg, 0.18 mmol), and HOBt (28 mg, 0.21 mmol) was added, followed by EDC (32 mg, 0.21 mmol). The vial was closed with a screw cap and shaken at r.t. over night. The mixture was treated with 0.1 ml TFA, filtered and purified by preparative HPLC to give the TFA salt. Conversion of the TFA salt into the HCl salt (and deprotection of amines containing a BOC-protection group) was achieved by shaking the compound with 2 ml 4M HCl in dioxane at r.t. overnight. Then 5 ml water were added and the mixture was freeze-dried to obtain the final product as the hydrochloride salt (17 mg, 19percent). LC/MS (Method LC10): Rt=2.23 min; m/z=428.22 [M+H]+. 1H-NMR (500 MHz, d6-DMSO): 2.30 (s, 1H), 2.63 (s, 3H), 2.85-2.95 (m, 2H), 3.62-3.68 (m, 4H), 4.31-4.43 (m, 1H), 6.22 (m, 1H), 6.90 (d, 2H), 7.2-7.6 (m, 4H), 7.70 (s, 1H), 8.07 (d, 2H).
The synthetic route of 5271-27-2 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; SANOFI; HACHTEL, Stephanie; PLETTENBURG, Oliver; SCHOENAU, Christian; LOEHN, Matthias; PFEIFFER-MAREK, Stefania; MENDEZ-PEREZ, Maria; KANNT, Aimo; DEDIO, Juergen; KOHLMANN, Markus; SCHIFFER, Alexander; BEGIS, Guillaume; DUCLOS, Olivier; JEANNOT, Frederic; US2013/85128; (2013); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics